Contents 2 min read

Claim and source comparison

5-HTP: depression research, an interaction case and plasma measurements.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

In the Cochrane review, only 2 studies with 64 patients in total met the analysis criteria for 5-HTP and tryptophan.

The review considered two different substances together. This evidence cannot establish the effectiveness or long-term safety of 5-HTP alone for depression.

Source 2 · Abstract read

Human case report / case review

A 2017 case report described severe serotonin syndrome in a patient taking several products, including sertraline and 5-HTP.

Other exposures and uncertain doses limit causal interpretation. A single case cannot establish the frequency of an interaction or a safe dose.

Source 5 · Full text read

Human pharmacokinetic study

In a 1978 study of 5 participants, plasma half-life after a single oral dose was 2.2–3.0 hours. It was 5.5 hours in one participant during long-term carbidopa use.

These are plasma measurements under specific study conditions. They do not establish effect duration, repeat dosing or the safety of adding carbidopa.

Source 6 · Abstract read

Our evidence and source methodology

5-HTP: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

⚠ Critical Interaction Warning - Serotonin Syndrome

5-HTP should not be combined with serotonergic medicines; serotonin syndrome can be life-threatening. Adding carbidopa is not a safety solution and belongs only within physician-directed treatment. Long-term safety is uncertain.

What is 5-HTP?

5-HTP (5-Hydroxytryptophan) is a compound produced in the body from the essential amino acid tryptophan and is a direct intermediate step in the synthesis of serotonin (5-HT). Commercial supplements often Griffonia simplicifolia It is obtained from the seeds of the West African plant called.

Unlike tryptophan, 5-HTP bypasses the rate-limiting enzyme tryptophan hydroxylase and converts directly to serotonin after crossing the blood-brain barrier. For this reason, it is being investigated as a serotonin precursor that may have an effect on mood, sleep patterns and appetite.

Mechanism of Effect

5-HTP: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans. This schematic mechanism illustration does not establish clinical benefit in humans, a receptor reset or a safe dosing schedule.

5-HTP is a precursor converted to serotonin by AADC. Serotonin’s role in melatonin synthesis does not by itself show that 5-HTP supplements treat insomnia or correct a serotonin deficiency.

Clinical Evidence

In the Cochrane review by Shaw et al. (2002), only 2 trials totaling 64 patients met the inclusion criteria for 5-HTP and tryptophan. This small pooled dataset does not establish 5-HTP alone as a proven depression treatment; evidence on efficacy and safety was insufficient.

Dose information and research limits

A standard dose of 5-HTP with established safety and effectiveness for sleep or depression has not been determined.

Safety and Side Effects

Long-term safety of 5-HTP has not been adequately studied; a “reasonable dose” does not establish safety. Nausea and other digestive symptoms may occur. A possible link with eosinophilia-myalgia syndrome (EMS), including the role of impurities, remains unresolved; product testing cannot guarantee clinical safety. Combining it with serotonergic medicines can cause life-threatening serotonin syndrome.

Who Does It Interact With?

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Birdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Alternative Medicine Review, 3(4), 271–280. PubMed · PMID 9727088
  2. Shaw K, Turner J, Del Mar C. (2002). Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, (1), CD003198. PubMed · PMID 11869656
  3. Turner EH, et al. (2006). Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics, 109(3), 325–338. PubMed · PMID 16023217
  4. Das YT, et al. (2004). Safety of 5-hydroxy-L-tryptophan. Toxicology Letters, 150(1), 111–122. PubMed · PMID 15068828
  5. Patel YA, Marzella N. (2017). Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome. American Journal of Case Reports, 18, 926–930. PubMed · PMID 28839121
  6. Magnussen I, Engbaek F. (1978). The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man. Acta Pharmacologica et Toxicologica, 43(1), 36–42. PubMed · PMID 309271

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions